Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Mutation of the nm23 gene, loss of heterozygosity at the nm23 locus and K-ras mutation in ovarian carcinoma: correlation with tumour progression and nm23 gene expression.
PMID 7669582 · PMC2033876 · British journal of cancer · 1995 · 8 claims · 5 setups
A novel missense mutation (TGG→CGG, Trp133→Arg) in nm23-H2 was found in one stage III serous ovarian carcinoma
-
Full-text index only
Ovarian cancer has frequent loss of heterozygosity at chromosome 12p12.3-13.1 (region of TEL and Kip1 loci) and chromosome 12q23-ter: evidence for two new tumour-suppressor genes.
PMID 9155043 · PMC2228239 · British journal of cancer · 1997 · 8 claims · 4 setups
Two commonly deleted regions on chromosome 12 were identified in ovarian cancer: 12p12.3-13.1 (6/23 samples) and 12q23-ter (7/23 samples)
-
Full-text index only
Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers.
PMID 18182111 · PMC2266762 · BMC cancer · 2008 · 8 claims · 4 setups
No somatic mutations were found in the entire tyrosine kinase domain (exons 18-24) of EGFR or HER2-neu in 68 tissue samples from 52 ovarian cancer patients.
-
Full-text index only
BRCA1 5382insC mutation in sporadic and familial breast and ovarian carcinoma in Scotland.
PMID 9155062 · PMC2228233 · British journal of cancer · 1997 · 6 claims · 4 setups
A restriction site-generating PCR (RG-PCR) assay was developed to detect the BRCA1 5382insC mutation.
-
Full-text index only
Epithelial ovarian cancer: influence of polymorphism at the glutathione S-transferase GSTM1 and GSTT1 loci on p53 expression.
PMID 8956789 · PMC2077203 · British journal of cancer · 1996 · 8 claims · 4 setups
GSTM1, GSTT1 and CYP2D6 genotype/allele frequencies did not differ significantly between 84 ovarian cancer cases and 325 controls, showing no association with disease susceptibility.
-
Full-text index only
Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy.
PMID 15601541 · PMC3525069 · Human genomics · 2004 · 8 claims · 6 setups
DNA microarray gene expression profiling generates robust molecular classifications for many tumour types (brain, breast, colon, gastric, kidney, leukaemia, lymphoma, lung, melanoma, ovary, prostate, etc.)
-
Full-text index only
High resolution melting for mutation scanning of TP53 exons 5-8.
PMID 17764544 · PMC2025602 · BMC cancer · 2007 · 7 claims · 5 setups
HRM is an effective technique for rapid scanning of TP53 mutations that can markedly reduce required sequencing
-
Full-text index only
Limited clinical relevance of mitochondrial DNA mutation and gene expression analyses in ovarian cancer.
PMID 18842121 · PMC2571110 · BMC cancer · 2008 · 8 claims · 2 setups
Somatic mutations in the mtDNA D-loop are found in 57% of ovarian cancer samples, mostly C-tract length changes and substitutions
-
Full-text index only
No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin.
PMID 16095531 · PMC1199587 · BMC cancer · 2005 · 6 claims · 4 setups
TUBB exon 4 mutations are not found in primary ovarian carcinomas treated with paclitaxel/cisplatin
-
Full-text index only
25th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 10-14 December 2002 Update on preclinical and translational research.
PMID 12631391 · PMC154153 · Breast cancer research : BCR · 2003 · 8 claims · 8 setups
Growth factor signalling (EGF/HER-2/MAPK, AKT) phosphorylates the oestrogen receptor and drives development of endocrine-resistant breast cancer